Good morning :)
$
₹
Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

NBIX

NASDAQ
Asset Logo

Neurocrine Biosciences Inc

NBIX

NASDAQ
$161.752.58% (-4.29)
$
₹
$161.752.58% (-4.29)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Large Cap

With a market cap of $16.8B the stock is ranked 762

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

24.45
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

4.00
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$6.74
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.29
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

20.91%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 29 analysts reports

Buy
25 analysts
Hold
4 analysts
Sell
0 analyst

Price Upside

+24.53%

Earnings Growth

+66.26%

Rev. Growth

+36.46%

See Detailed Forecast

Company Profile

Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 24.53% growth, versus a trailing 3-year CAGR of 13.35%.

2026
Current$166.05Baseline
Analyst Target - 1 year
Target$206.79+24.53%

All values in $

202220232024202520262027$137.49$167.48$197.48Target+24.53%
2026
Current$166.05Baseline
Analyst Target - 1 year
Target$206.79+24.53%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 36.46% growth, versus a trailing 3-year CAGR of 24.32%.

2025
Current$2.86Baseline
Forecast for Dec 2026
High$4.06+42.24%
Average$3.90+36.46%
Low$3.85+34.67%

All values in $ Billion

2021202220232024202520261.131.481.882.352.86Low+34.67%Average+36.46%High+42.24%
2025
Current$2.86Baseline
Forecast for Dec 2026
High$4.06+42.24%
Average$3.90+36.46%
Low$3.85+34.67%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 66.26% growth, versus a trailing 3-year CAGR of 22.75%.

2025
Current$6.4Baseline
Forecast for Dec 2026
High$11.11+73.67%
Average$10.64+66.26%
Low$10.39+62.34%

All values in $

2021202220232024202520261.83.463.826.336.4Low+62.34%Average+66.26%High+73.67%
2025
Current$6.4Baseline
Forecast for Dec 2026
High$11.11+73.67%
Average$10.64+66.26%
Low$10.39+62.34%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0.8
0.1
0.8
0.1
0.9
0.1
1.1
0.2
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue0.590.620.620.570.680.790.800.810.951.12
Net Income0.060.120.1000.100.200.150.190.140.20
Net Profit Margin11.01%20.86%16.42%1.37%15.63%26.35%19.08%24.29%15.05%18.39%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Neurocrine Biosciences Inc 24.454.000.29
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare NBIX with any stock or ETF
Compare NBIX with any stock or ETF
Comparing from
NBIX
ABBV
AMGN
Loading...

Frequently asked questions

  1. Neurocrine Biosciences Inc (NBIX) share price today is $161.75 as of November 6, 2026 at 1:13 AM IST. The stock touched a day high of $167.19 and a day low of $161.19.

  2. Neurocrine Biosciences Inc stock trades on NASDAQ under the ticker symbol NBIX.

  3. Neurocrine Biosciences Inc's market capitalization is $16.75B as of November 6, 2026 at 1:13 AM IST.

  4. Neurocrine Biosciences Inc's price-to-earnings (P/E) ratio is 24.45 as of November 5, 2026.

  5. Neurocrine Biosciences Inc's price-to-book (P/B) ratio is 4.00 as of November 5, 2026.

  6. Yes, You can buy Neurocrine Biosciences Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Neurocrine Biosciences Inc shares in three steps: 1. Search Neurocrine Biosciences Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Neurocrine Biosciences Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Neurocrine Biosciences Inc (NBIX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0618 shares at the current price of $161.75.

Loading...